TriVascular
TriVascular Tech’s stent graft recall could hurt the bottom line
California medtech maker TriVascular Technologies (NSDQ:TRIV) issued an update today on the recall of certain of its Ovation Prime aortic stent grafts, advising that the measure may drag down full-year revenues.
TriVascular Technologies recalls 30 Ovation Prime stent grafts
IPO or bust for emerging medtechs
IPO: Stent graft maker Trivascular Tech. jumps on opening day
Trivascular Technologies (NSDQ:TRIV) shares made a good showing on their first day on the Nasdaq stock exchange, having gained 15% by about 4 p.m. EST.
Stryker hits a new lifetime high in shares | Medtech Wall Street news for the week of Apr. 7, 2014
TriVascular Technologies sets price range for $98M IPO
TriVascular Technologies said it could raise as much as $98 million from its planned initial public offering after setting the per-share price range at $13-$15.
That would set the top end of the 6.5-million-share offering at $97.5 million, or $84.5 million at the low end.
Biomet puts itself back on public market | Medtech Wall Street news for the week of Mar. 10, 2014
Biomet announces IPO plans
March 7, 2014 by Brad Perriello
Biomet is planning to put itself back on the public market after a 7-year run under private equity ownership, the orthopedics giant said today.
TriVascular Tech aims for $100M IPO
California medical device maker TriVascular Technologies is looking to raise as much as $100 million through its initial public offering, the details of which have yet to be finalized.
TriVascular adds $2M in options round
TriVascular Inc. sold $1.9 million in an options offering, adding to a $40 million Series E funding round it logged last month.
Santa Rosa, Calif.-based TriVascular makes the Ovation line of stent grafts for treating abdominal aortic aneurysms.
The company sold options and convertible notes to 2 unnamed investors, according to a regulatory filing.
TriVascular raises $40M Series E round
TriVascular Inc. said it’s added another $40 million to its coffers in a Series E round it plans to use to expand its commercial footprint and " to fuel product pipeline and clinical research activities."
Santa Rosa, Calif.-based TriVascular makes the Ovation line of stent grafts for treating abdominal aortic aneurysms.